Morphological Study in B16F10 Murine Melanoma Cells after Photodynamic Hyperthermal Therapy with Indocyanine Green (ICG)

Radzi, Rozanaliza; Osaki, Tomohiro; Tsuka, Takeshi; Imagawa, Tomohiro; Minami, Saburo; Okamoto, Yoshiharu

doi:10.1292/jvms.11-0467

Cited by 17 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously investigated the effects of PHT on B16F10 murine melanoma cells in vitro [31,32]. Our results demonstrated that PHT induces early morphological changes in tumor cells that promote more cell death than hyperthermia alone.…”

Section: Discussionmentioning

confidence: 88%

Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma

et al. 2014

Self Cite

View full text Add to dashboard Cite

Sixteen cases of malignant soft tissue sarcoma (STS; 10 canines and six felines) were treated with a novel triple therapy that combined photodynamic therapy, hyperthermia using indocyanine green with a broadband light source, and local chemotherapy after surgical tumor resection. This triple therapy was called photodynamic hyperthermal chemotherapy (PHCT). In all cases, the surgical margin was insufficient. In one feline case, PHCT was performed without surgical resection. PHCT was performed over an interval of 1 to 2 weeks and was repeated three to 21 times. No severe side effects, including severe skin burns, necrosis, or skin suture rupture, were observed in any of the animals. No disease recurrence was observed in seven out of 10 (70.0%) dogs and three out of six (50.0%) cats over the follow-up periods ranging from 238 to 1901 days. These results suggest that PHCT decreases the risk of STS recurrence. PHCT should therefore be considered an adjuvant therapy for treating companion animals with STS in veterinary medicine.

show abstract

Section: Discussionmentioning

confidence: 88%

Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…As ICG has low toxicity, it is used for various medical examinations, such as the measurement of cardiac output and hepatic function, ophthalmic angiography, and the detection of sentinel lymph nodes (13)(14)(15)(16). In addition, ICG has the properties to act as a near-infrared ray (NIR) photosensitizer for PDT, generating heat and ROS by NIR irradiation (17). Because of its short half-life of 3 minutes, light shielding is not necessary after treatment.…”

Section: Introductionmentioning

confidence: 99%

Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment

Tamai

Mizushima

et al. 2018

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Minimally invasive treatment is getting more and more important in an aging society. The purpose of this study was to explore the possibility of ICG loaded on super carbonate apatite (sCA) nanoparticles as a novel photodynamic therapy (PDT) against cancers. Using colon cancer cells, ICG uptake and anti-tumor effects were examined between the treatments of ICG and sCA-ICG. Reactive oxygen species (ROS) production and temperature rise were also evaluated to explore the underlying mechanism. Atomic force microscopy revealed that the size of sCA-ICG ranged from 10 to 20 nm. In aqueous solution with 0.5% albumin, the temperature increase after laser irradiation was 27.1°C and 23.1°C in sCA-ICG and ICG, respectively (control DW: 5.7°C). A significant increase in ROS generation was noted in cell cultures treated with sCA-ICG plus irradiation compared with those treated with ICG plus irradiation ( < 0.01). Uptake of ICG in the tumor cells significantly increased in sCA-ICG compared with ICG and The fluorescence signals of ICG in the tumor, liver, and kidney faded away in both treatments by 24 hours. Finally, the HT29 tumors treated with sCA-ICG followed by irradiation exhibited drastic tumor growth retardation ( < 0.01), whereas irradiation of tumors after injection of ICG did not inhibit tumor growth. This study shows that sCA is a useful vehicle for ICG-based PDT. Quick withdrawal of ICG from normal organs is unique to sCA-ICG and contrasts with the other nanoparticles remaining in normal organs for a long time. .

show abstract

“…Photodynamic hyperthermal therapy (PHT) (16,17), photodynamic hyperthermal CT (PHCT) (18,19) and CT were performed, with lupeol administered as an adjuvant therapy. PHT is a local treatment combining photo- ---187 187 Alive C06 II Partial ---180 180 Alive C07 II Partial PHCT --120 420 Alive C08 II Partial ---201 201 Alive C09 III Partial ---248 248 Alive C10 III Partial PHT --189 189 Alive C11 III Partial ---39 39 Alive DFT, disease-free time; ST, survival time; PHCT, photodynamic hyperthermal chemotherapy; PHT, photodynamic hyperthermal therapy.…”

Section: Subjectsmentioning

confidence: 99%

“…dynamic therapy and hyperthermia that uses indocyanine green as a photosensitizer (16,17). PHCT is an advanced form of PHT, in combination with carboplatin CT (18,19).…”

Section: Subjectsmentioning

confidence: 99%

Clinical systemic lupeol administration for canine oral malignant melanoma

Yokoe¹,

Aso²,

Hata³

et al. 2014

Molecular and Clinical Oncology

Self Cite

View full text Add to dashboard Cite

Abstract. Canine oral malignant melanoma (COMM) is the most aggressive malignant tumor in dogs. Lupeol is a triterpene extracted from various fruits and vegetables that reportedly inhibits melanoma cell proliferation in vitro and in vivo. In this study, the efficacy of subcutaneous lupeol for spontaneous COMM was evaluated. A total of 11 dogs (3, 5 and 3 dogs diagnosed with clinical stage I, II and III melanoma, respectively) were evaluated. Subcutaneous lupeol (10 mg/kg) was administered postoperatively at various time points to treat these 11 COMM cases. Of the 11 subjects, 7 exhibited no local recurrence 180 days postoperatively and no severe adverse effects were observed in any of the cases. Furthermore, no distant metastasis was observed during the experimental period. Therefore, systemic lupeol may prevent local tumor progression and distant metastasis and may be a novel adjuvant treatment for the treatment of COMM. IntroductionCanine oral malignant melanoma (COMM) is the most common malignancy in dogs, accounting for 30-40% of all oral tumors (1,2). COMM is characterized by extensive local invasion, as well as distant metastasis (2). Melanoma treatment includes radiation therapy and chemotherapy (CT), either alone, as an adjuvant therapy following surgery, or in combination (2). Although radiation therapy provides effective local tumor control, it is only performed in selected facilities (3-5).In addition, radiation therapy may be costly and, hence, beyond the financial means of some owners. Several reports have investigated the efficacy of CT in COMM, but there is no definitive evidence regarding its effectiveness (5,6,7-9). Therefore, there is a need for an alternative treatment for COMM.Lupeol is a triterpene found in fruits such as olives, mangoes, strawberries, grapes and figs, numerous vegetables and several medicinal plants (10). Previous studies reported that lupeol has antitumor properties (11,12) and several reports indicated that lupeol inhibits melanoma cell proliferation in vitro and in vivo (13,14). Recently, Nitta et al (14) reported that systemic lupeol administration inhibited tumor growth in a melanoma-bearing mouse model; however, there is no report evaluating its clinical efficacy in COMM. In this study, we aimed to evaluate the efficacy of subcutaneous lupeol as an adjuvant therapy for spontaneous COMM. Subjects and methods Subjects.A total of 11 dogs were included in this study. The characteristics of the sublects are summarized in Table I. The represented breeds included 2 miniature Dachshunds, 2 Beagles, 2 miniature Schnauzers, 1 Golden Retriever, 1 Labrador Retriever, 1 American Cocker Spaniel, 1 Cavalier King Charles Spaniel and 1 mixed-breed dog. The dogs ranged in age between 8 and 17 years. The tumors in all 11 dogs were classified according to the TNM classification (1,2) as follows: 3 dogs had stage I, 5 dogs had stage II and 3 dogs had stage III disease (Table I). Two cases of cancer recurrence were included (C04 and C07). This study was conducted between April, 2010 and M...

show abstract

Morphological Study in B16F10 Murine Melanoma Cells after Photodynamic Hyperthermal Therapy with Indocyanine Green (ICG)

Cited by 17 publications

References 37 publications

Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma

Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma

Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment

Clinical systemic lupeol administration for canine oral malignant melanoma

Contact Info

Product

Resources

About